Last reviewed · How we verify
NCT00665041
A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Single-centre Pilot Study Assessing the Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome
Phase 2 trial testing Quinagolide in Ovarian Hyperstimulation Syndrome in 30 participants. Completed in 1 October 2008.
1 August 2008
Quick facts
| Lead sponsor | Instituto Valenciano de Infertilidad, IVI VALENCIA |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 May 2008 |
| Primary completion | 1 August 2008 |
| Estimated completion | 1 October 2008 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Quinagolide — full drug profile →
Conditions studied
- Ovarian Hyperstimulation Syndrome — all drugs for Ovarian Hyperstimulation Syndrome →
Sponsor
Instituto Valenciano de Infertilidad, IVI VALENCIA — full company profile →
Who can join
Adults 21 to 34, female only, with Ovarian Hyperstimulation Syndrome. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
To assess the tolerability of quinagolide 200 μg/day in a dose-titration regimen in oocyte donors undergoing controlled ovarian hyperstimulation and at risk of developing OHSS
Time frame: 21 days
Sponsor's own description
Assess the tolerability of quinagolide 200 μg/day in a dose-titration regimen in oocyte donors undergoing controlled ovarian hyperstimulation and at risk of developing OHSS Secondary Objectives Estimate the effects of a quinagolide dose-titration regimen compared to placebo in peritoneal fluid accumulation, incidence of ascites, OHSS symptoms and clinical laboratory parameters of haemoconcentration
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00665041
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Instituto Valenciano de Infertilidad, IVI VALENCIA trials
Trials by the same sponsor.
- NCT06193135 — Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitar · NA · recruiting
- NCT06384794 — Study of the ZyMōt Sperm Selection Method and Its Effect on Embryo Ploidy. · NA · recruiting
- NCT06103383 — Second Phase of the Pilot Study for Obtaining Mature Oocytes by in Vitro Maturation in Oocyte-donor Women · NA · unknown
- NCT05440019 — Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration · completed
- NCT05161338 — Impact of Vaginal Microbiome on Vaginal Absorption of Exogenous Progesterone: a Pilot Study. · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00665041 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto Valenciano de Infertilidad, IVI VALENCIA
- Last refreshed: 16 September 2009
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00665041.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing